Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

2424 - Irinotecan Combined with Oxaliplatin and S1 in Patients with Metastatic Pancreatic Adenocarcinoma


29 Sep 2019


Poster Display session 2


Tumour Site

Pancreatic Adenocarcinoma


Keke Nie


Annals of Oncology (2019) 30 (suppl_5): v253-v324. 10.1093/annonc/mdz247


K. Nie1, X. Guo2, X. Zhou3, Z. Zhang4, C. Zhang1, K. Lan1, Y. Ji1

Author affiliations

  • 1 Medical Oncology, Qingdao Central Hospital, the 2nd Affiliated Qingdao Central Hospital of Qingdao University, 266041 - Qingdao/CN
  • 2 Medical Oncology, Pingdu People's Hospital, 2266700 - Qingdao/CN
  • 3 Clinical Research, Qingdao Central Hospital, the 2nd Affiliated Qingdao Central Hospital of Qingdao University, 266041 - Qingdao/CN
  • 4 Radiotherapy Department, Qingdao Cancer Hospital, 266041 - Qingdao/CN


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 2424


Prognosis of metastatic pancreatic adenocarcinoma is gloomy. To elicit a chemotherapy regimen with higher efficiency and with lower toxicities is critical important.


This was a one arm, phase 2, three-center study. Enrolled patients were histological or pathologically confirmed; treatment naïve metastatic pancreatic adenocarcinoma. Enrolled patients were 18 years or older, with at least one measurable lesion and performance status between 0-2 with ECOG score. Irrinotecan 165 mg/m2 and oxaliplatin 85 mg/m2 were administered intravenous infusion on days 1, and S1 40 mg/m2 was administered orally on day 1-14, every 21 day a cycle until progressive disease or intolerable toxicities or patient death. The primary endpoint was overall survival and the second endpoints were progression-free survival and toxicities.


A total of 41 patients were enrolled, median age was 59 year-old. There were 18 men and 23 women. The median progression-free survival was 4.33 (95% CI: 2.83-5.88) and median overall survival was 11.00 (95% CI: 9.16-12.84). There were 38 patients validated for efficiency evaluation. There was no complete response, the partial response rate, stable disease and progression disease was 42.11% (16/38), 31.58% (12/38) and 26.32% (10/38) respectively. The most common adverse effect was mild to moderate nausea, vomiting, neutropenia and thrombocytopenia. The 3/4 degree neutropenia and thrombocytopenia were 29.27% (12/41) and 12.20% (5/41) respectively.


Irinotecan combined with oxaliplatin and S1 was effective in metastatic pancreatic adenocarcinoma; its toxicities were mild to moderate and tolerable. Furthermore, patients to enrol the study is needed.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.